Icon ( (ICLR) ) has issued an update.
On March 3, 2025, ICON plc announced a delay in their large-scale next-generation COVID vaccine study, initially highlighted during their February 20, 2025 earnings call. The sponsor-induced delay is expected to last 90 days, pushing the study’s recommencement to late Q2 2025. While this postponement will affect the company’s revenue for the first half of the year, ICON maintains its financial guidance for the full year 2025, indicating confidence in their overall fiscal strategy despite the temporary setback.
More about Icon
ICON plc is a company operating in the healthcare industry, specializing in clinical research and development services. It focuses on providing comprehensive solutions for pharmaceutical, biotechnology, and medical device industries, aiming to enhance the development of medical products and therapies.
YTD Price Performance: -10.63%
Average Trading Volume: 964,414
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.35B
For detailed information about ICLR stock, go to TipRanks’ Stock Analysis page.